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Introduction
Parkinson disease (PD) is the second most common neu-
rodegenerative disease after Alzheimer disease (1). PD is
clinically characterized by disabling motor abnormalities,
which include tremor, muscle stiffness, paucity of volun-
tary movements, and postural instability (2), and its main
neuropathological feature is the loss of substantia nigra
pars compacta (SNpc) dopaminergic neurons (3).
While PD is a sporadic condition of uncertain etiol-
ogy (2), several lines of evidence suggest that a defect
in oxidative phosphorylation contributes to its patho-
genesis. For instance, 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP), a neurotoxin that blocks com-
plex I (NADH-ubiquinone oxidoreductase) of the
mitochondrial electron transport chain (4), recapitu-
lates in humans the hallmarks of PD (5). Further-
more, reduction in complex I activity has been report-
ed in PD tissues (reviewed in ref. 6). This defect is not
confined only to the brain (7), since low complex I
activity has also been found in platelets from PD
patients (8, 9) and in cybrid cells engineered to contain
mitochondria derived from platelets of patients suf-
fering from PD (10).
D-β-Hydroxybutyrate (DβHB) is a ketone body pro-
duced by hepatocytes and, to a lesser extent, by astro-
cytes (11). It is an alternative source of energy in the
brain when glucose supply is depleted such as during
starvation (12). In vitro DβHB prevents neuronal dam-
age seen following glucose deprivation (13) and mito-
chondrial poison exposure (14). Herein, we show that
DβHB infusion protects SNpc dopaminergic neurons
against MPTP in a dose-dependent and stereospecific
manner and prevents the development of PD-like
motor abnormalities in mice. We also provide in vivo
and in vitro evidence that DβHB protects not by alle-
viating MPTP-related complex I inhibition, but by
enhancing oxidative phosphorylation via a mechanism
dependent on mitochondrial complex II (succinate-
ubiquinone oxidoreductase).
Methods
Animals and treatment. All animals were 8- to 10-week-old
male C57BL mice (Charles River Laboratories, Wilm-
ington, Massachusetts, USA). Mice were divided into
four groups: vehicle (i.e., saline), DβHB, L-hydroxybu-
tyrate (LβHB), and DβHB plus 3-nitropropionic acid 
(3-NP). Vehicle, DβHB (1.6, 0.8, or 0.4 mmol/kg/d in
saline, pH 7.4; Sigma-Aldrich, St. Louis, Missouri, USA),
and LβHB (1.6 mmol/kg/d in saline, pH 7.4; Sigma-
Aldrich) were administered subcutaneously (1 µl/h)
using Alzet mini-osmotic pumps (DURECT Corp.,
Cupertino, California, USA). 3-NP (Sigma-Aldrich; 
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15 mg/kg, in 0.1 M PBS adjusted to pH 7.4) was given
intraperitoneally 2 hours before the implantation on
the first day and then once a day until the animals were
sacrificed. This dosage of 3-NP was selected to inhibit
complex II but not to induce cell loss. After surgery, ani-
mals were allowed to rest for 1 day. Each mouse was
then randomly assigned to receive four intraperitoneal
injections of either MPTP (18 mg/kg of free base in
saline; Sigma-Aldrich) or saline at 2-hour intervals.
Tyrosine hydroxylase immunostaining and quantitative
morphology. Seven days after the last MPTP injection,
mice were killed and their brains were processed for
immunohistochemical studies. Sections (30 µm) were
incubated with a polyclonal anti-tyrosine hydroxylase
(TH; 1,000 dilution; Calbiochem-Novabiochem Corp.,
San Diego, California, USA) for 48 hours at 4°C.
Biotinylated secondary antibodies followed by avidin-
biotin complex were used. Immunoreactivity was visu-
alized by incubation in 3,3′-diaminobenzidine/glu-
cose/glucose oxidase. Total numbers of TH-positive
neurons in SNpc were counted stereologically using the
optical fractionator method (15). Striatal OD of TH
immunostaining, determined by the Scion Image pro-
gram (Scion Corp., Frederick, Maryland, USA), was
used as an index of striatal density of TH innervation
(16). The concentration of anti-TH antibody and 
3,3′-diaminobenzidine (DAB) and the duration of incu-
bation of striatal sections in DAB were optimized to fall
within the linear range of the plot of the immunos-
taining intensities and the scanned ODs.
Measurement of DβHB and succinate levels. At different
time points after the implantation of the osmotic
pumps, blood was collected from tails, and brains were
quickly removed, freeze-clamped under liquid nitrogen,
and stored at –80°C. Frozen tissues were treated with
perchloric acid and neutralized with sodium hydroxide
as previously described (17). Both DβHB and succinate
were measured spectrophotometrically at 340 nm using
commercial kits from Sigma-Aldrich and from Roche
Molecular Biochemicals (Indianapolis, Indiana, USA)
respectively, following the manufacturers’ instructions.
Measurement of striatal 1-methyl-4-phenylpyridinium lev-
els. Mice infused with either saline or DβHB (1.6 mmol/
kg/d) were injected with MPTP (18 mg/kg) as described
above and killed 90 minutes after the fourth injection.
HPLC with UV detection (295 nm) was used to meas-
ure striatal 1-methyl-4-phenylpyridinium (MPP+) lev-
els as previously described (18) with the following mod-
ifications: a reverse-phase Altima C18 column (Alltech
Associates Inc., Deerfield, Illinois, USA) and a mobile
phase consisting of 89% 50 mM KH2PO4 and 11% ace-
tonitrile were used. Data represent mean ± SEM of five
mice per group.
Synaptosomal uptake of MPP +. Striata were dissected out
from naive mice and processed for uptake experiments
as described previously (19) with a few modifications.
Briefly, striata were homogenized in 0.32 M sucrose and
centrifuged at 700 g, 4°C, for 10 minutes. The super-
natant was removed and centrifuged at 27,000 g for 30
minutes. The resulting synaptosomal pellet was sus-
pended at 1.2 mg/ml (original wet weight) in Krebs-
Ringer phosphate buffer (pH 7.4). The uptake reaction
was initiated by addition of 0.6 mg of synaptosomes to
tubes containing [3H]MPP+ (∼4 nM, ∼800,000 degrada-
tions per minute, specific activity 31.6 Ci/mmol; Amer-
ican Radiolabeled Chemicals Inc., St. Louis, Missouri,
USA) in the absence or presence of DβHB (up to 5 mM)
at 37°C for 6 minutes. Nonspecific uptake was assessed
in the presence of 10 µM mazindol. Data represent
mean ± SEM of three mice per group.
Isolation of brain mitochondria. Brains from C57BL mice
were homogenized in isolation buffer (225 mM man-
nitol, 75 mM sucrose, 1 mM EGTA, 5 mM HEPES, and
2 mg/ml fat-free BSA) using a motorized Dounce
homogenizer with eight up-and-down strokes. The
homogenate was centrifuged at 1,000 g for 10 minutes,
and the resulting supernatant was layered onto 5 ml of
7.5% Ficoll medium on top of 5 ml of 10% Ficoll medi-
um and centrifuged at 79,000 g for 30 minutes (the
Ficoll medium contained 0.3 M sucrose, 50 µM EGTA,
and 10 mM HEPES). The mitochondrial pellet was
resuspended in isolation buffer. Protein concentrations
were determined by the bicinchoninic assay (Pierce
Chemical Co., Rockford, Illinois, USA) method with
BSA as a standard protein.
Mitochondrial accumulation of MPP+. Brain mitochondria
were isolated and resuspended in buffer as described pre-
viously (20) but with a few modifications. The uptake
reaction was initiated by addition of 0.6 mg of mito-
chondria to tubes containing 5 µM [3H]MPP+ and 45
µM MPP+ in the absence or presence of DβHB (up to 5
mM) at 25°C for 3 minutes. Nonspecific uptake was
assessed in the presence of 5 µM carbonylcyanide p-tri-
fluoromethoxyphenylhydrazone (FCCP). Data represent
mean ± SEM of four or five mice per group.
Polarography. Brain mitochondria were suspended in
respiration buffer consisting of 225 mM mannitol, 75
mM sucrose, 10 mM KCl, 5 mM HEPES, 5 mM K2HPO4,
and freshly added 1 mg/ml defatted BSA at 30°C, and
oxygen-consumption rates were measured in a closed-
chamber cuvette with a mini–stirring bar using a Clark-
type electrode (Hansatech Instruments Ltd., Norfolk,
United Kingdom). For each reading, 300 µg protein was
used in a final 1-ml respiration buffer, and all mito-
chondria preparations had an average respiratory con-
trol ratio of at least 5 when 10 mM glutamate and 5 mM
malate were used as NADH-linked substrates.
ATP measurements. Samples were prepared under con-
ditions identical to those of polarographical study.
Mitochondria suspended in respiration buffer were
incubated in the presence or absence of different sub-
strates or inhibitors using the same incubation times as
those of polarographical study. Where 3-NP was used,
it was added from the beginning with MPP+ (5 minutes)
or rotenone (2.5 minutes) to mitochondria before the
addition of DβHB. When the reaction was stopped,
mitochondrial suspension from the cuvette was lysed in
an equal volume of lysis buffer from the ATP biolumi-
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nescence assay kit (Roche Molecular Biochemicals), and
the content of ATP was measured according to the man-
ufacturer’s instructions. Light emitted from luciferase-
mediated reaction was captured in a tube luminometer
and calculated from a log-log plot of the standard curve
of known ATP concentrations.
Measurements of mitochondrial H2O2 production. Samples
were prepared under conditions identical to those of
polarographical study. Mitochondria suspended in res-
piration buffer were incubated in the presence or
absence of different substrates or inhibitors using the
same incubation times as those of polarographical
study. Phenazine methosulfate (0.1 mM) was used to
oxidize NADH (21). Hydrogen peroxide, converted
from superoxide by manganese-superoxide dismutase,
was measured using 5 µM Amplex red (Molecular
Probes, Eugene, Oregon, USA) and 5 U/ml HRP. Fluo-
rescence was detected by a Perkin-Elmer (Boston, Mass-
achusetts, USA) LS55 spectrofluorometer with an exci-
tation wavelength of 550 nm (slit 1.5 nm) and an
emission wavelength of 585 nm (slit 3 nm). H2O2 pro-
duction was calculated from a standard curve generat-
ed from known concentrations of H2O2.
Measurements of mitochondrial transmembrane potential.
Safranine, a cationic fluorescence dye accumulated and
quenched inside energized mitochondria (22, 23) was
used to measure transmembrane potential (∆ψm).
Mitochondria were incubated with 10 mM glutamate,
5 mM malate, and 5 µM safranine (Sigma-Aldrich) in
respiration buffer 5 minutes before 5 mM DβHB was
added, and ∆ψm was monitored for an additional 5
minutes. FCCP (5 µM) was used as a positive control to
collapse ∆ψm. Fluorescence was detected by a Perkin-
Elmer LS55 spectrofluorometer with an excitation
wavelength of 495 nm (slit 3 nm) and an emission
wavelength of 586 nm (slit 5 nm). Data are reported in
arbitrary fluorescence units (AFUs).
Complex I activity. Largely based on protocols described
by Birch-Machin and Turnbull (24), brain mitochondria
were lysed by freeze-thawing in hypotonic buffer (25
mM KH2PO4 [pH 7.2], 5 mM MgCl2) three times. To ini-
tiate the reaction, 50 µg mitochondria were added to the
assay buffer (hypotonic buffer containing 65 µM
ubiquinone1, 130 µM NADH, 2 µg/ml antimycin A, and
2.5 mg/ml defatted BSA) in the absence or presence of
different concentrations of rotenone (2.5–15 µM) or
MPP+ (10–30 mM). The oxidation of NADH by complex
I was monitored at 340 nm spectrophotometrically for
3 minutes at 30°C prior to the addition of rotenone (2
µg/ml), after which the activity was measured for an
additional 3 minutes. The difference in rate before and
after the addition of rotenone (2 µg/ml) was used to cal-
culate complex I activity.
Complex II histochemistry. Animals were injected
intraperitoneally with either saline or 3-NP (15 mg/kg)
once daily for 8 days, the same regimen used in the ani-
mals that received DβHB. As described previously (25),
animals were perfused with PBS containing 10% glyc-
erol. Brains were rapidly removed, frozen in dry
ice–cooled isopentane, and stored at –80°C. Brains
were sectioned at 20 µm throughout the entire nigra
and striatum. Sections were mounted onto glass
microscope slides, and complex II activity was revealed
by incubation of sections at 37°C for 20 minutes in 50
mM phosphate buffer (pH 7.6) containing 50 mM suc-
cinate as a substrate and 0.3 mM Nitroblue tetrazoli-
um (NBT) as an electron acceptor.
Immunoblots. Total tissue proteins from ventral mid-
brains of MPTP- and saline-treated mice were isolated as
described previously (26), and 20 µg proteins were sepa-
rated on 12% SDS-PAGE. Membranes were blotted with
polyclonal anti–β-hydroxybutyrate dehydrogenase (1:100;
a generous gift from Andrew Marks, Columbia Universi-
ty, New York, New York, USA) and monoclonal anti–
β-actin (1:5,000) overnight at 4°C. Secondary antibodies
conjugated with HRP were used. Bands of interest were
analyzed and quantified using FluorChem 8800 (Alpha
Innotech Corp., San Leandro, California, USA).
Rotarod performance. The Economex system (Columbus
Instruments, Columbus, Ohio, USA), consisting of four
rotating rods of 3 cm diameter in separated compart-
ments, enables four mice to be recorded simultaneous-
ly. Seven days after MPTP or saline injections, implant-
ed pumps containing 1.6 mmol/kg/d DβHB were
removed, and mice (4–13 animals per group) were
allowed to recover from surgery and dehydration for an
additional 7 days. On the testing day, animals were first
pretrained three times (1 hour apart) using an accelerat-
ing mode. After these training sessions, the time on the
rod, with a maximum recording time of 240 seconds,
was recorded for successive rotational speeds (15, 18, 21,
24, 27, 30, 32, 36, and 40 rpm), and the overall rod per-
formance (ORP) for each mouse was calculated by the
trapezoidal method as the area under the curve in the
plot of time on the rod versus rotation speed (27). To
assess the responsiveness of the MPTP-related motor
deficit to dopaminergic stimulation, mice were injected
intraperitoneally with L-3,4-dihydroxyphenylalanine 
(L-DOPA) methyl ester/benserazide (100/25 mg/kg), and
Rotarod performance was assessed 45 minutes later.
Measurement of dopamine and its metabolite levels in stri-
atal and ventral midbrain tissues. Animals from the Rotar-
od study were sacrificed, and their striata and ventral
midbrains were dissected out and stored at –80°C until
analysis. On the day of the assay, striatal and ventral
midbrain tissues were sonicated in 50 and 10 volumes
(wt/vol), respectively, of 0.1 M perchloric acid contain-
ing 50 ng/ml dihydrobenzylamine as internal standard.
After centrifugation at 15,000 g for 15 minutes at 4°C,
20 µl of supernatant was injected onto a C18 reverse-
phase HR-80 catecholamine column (ESA Inc., Bed-
ford, Massachusetts, USA). The mobile phase consist-
ed of 94% 50 mM sodium phosphate/0.2 mM
EDTA/1.2 mM heptanesulfonic acid (pH 3.2) solution
and 6% methanol. The flow rate was 1.5 ml/min. Peaks
were detected by an ESA 8 Channel CoulArray system.
Data were collected and processed using the CoulArray
data analysis program (version 1.12).
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Statistical analysis. All values are expressed as mean ± SEM.
Differences between means were analyzed using one-
way ANOVA followed by Newman-Keuls post-hoc test-
ing for pairwise comparison. The null hypothesis was
rejected when P was greater than 0.05.
Results
MPTP upregulates DβHB-metabolizing enzyme and increas-
es utilization of DβHB in the brain. To assure sustained
high tissue levels of DβHB during the experiment, this
short-half-life (28) compound was infused subcuta-
neously at a dose of 1.6 mmol/kg/d for the entire 7 days.
This regimen seemed well tolerated and yielded a stable
plasma level of approximately 0.9 mM throughout the
7-day period. Likewise, brain
DβHB levels in mice intoxicat-
ed with MPTP did not signifi-
cantly change throughout the
experiment (Figure 1a). Brain
DβHB levels in mice that
received saline instead of receiv-
ing MPTP, 3-NP, or both were
significantly higher, at least at
the beginning of the experi-
ment (Figure 1a).
Circulating DβHB readily
crosses the blood-brain barrier
and enters mitochondria, where
it is metabolized by β-hydroxy-
butyrate dehydrogenase to ace-
toacetate; the latter is converted
to acetyl-CoA, which feeds into
the Krebs cycle (29). In saline-
injected control mice, β-hydroxybutyrate dehydrogenase
protein content in ventral midbrain (the brain region
that contains the SNpc) was detectable (Figure 1b). In
MPTP-injected mice, β-hydroxybutyrate dehydrogenase
protein content in ventral midbrain rose rapidly and
remained elevated for 2 days after the last injection of
MPTP (Figure 1b). These data suggest that MPTP-relat-
ed cellular stress is associated with a β-hydroxybutyrate
dehydrogenase upregulation, which in turn may facili-
tate utilization of DβHB in the brain.
DβHB attenuates MPTP-induced dopaminergic neurodegen-
eration. One day after implantation of pumps containing
either vehicle or DβHB, mice were injected with MPTP.
Seven days later, the brains of these animals were
processed for quantification of dopaminergic cell bod-
ies in the SNpc and of projecting dopaminergic fibers in
the striatum using TH immunostaining. In saline-inject-
ed mice infused with either vehicle or DβHB, numbers
of TH-positive neurons in the SNpc were identical (Table
1; Figure 2, a and b), as were TH ODs in the striatum
(Table 1; Figure 2, i and j). In MPTP-injected mice
infused with vehicle, there was an approximately 70%
loss of SNpc TH-positive neurons and an approximate-
ly 90% reduction of striatal TH ODs (Table 1; Figure 2, e
and m) compared with saline-injected controls (Table 1;
Figure 2, a and i). In contrast, in MPTP-injected mice
Figure 1
Brain levels of DβHB and β-hydroxybutyrate dehydrogenase (βHBD)
under different treatments. (a) One day after implantation of pumps
containing DβHB, animals were injected intraperitoneally with saline
(Sal), MPTP, or 3-NP as described in Methods, and brain levels of
DβHB were measured at 0 days (90 minutes after the fourth injec-
tion), 2 days, and 7 days thereafter. The utilization of DβHB was
increased when cells were under metabolic stress induced by these
toxins. n = 4–6; *P < 0.05 and **P < 0.01 compared with the respec-
tive control saline groups. (b) Western blot analysis of ventral mid-
brains from MPTP-intoxicated mice shows upregulation of this
enzyme as early as day 0. n = 4–5 per group; *P < 0.05 compared with
the control saline group. β-Actin is used to normalize βHBD values.
Table 1
TH- and Nissl-positive neurons in SNpc and striatal TH density
MPTP 3-NP Nigral TH Nigral Nissl Striatal TH 
OD (×100)
Vehicle – – 9,770 ± 694 15,525 ± 930 21.78 ± 1.90
DβHB (1.6 mmol/kg/d) – – 9,293 ± 590 14,880 ± 416 23.76 ± 2.10
LβHB (1.6 mmol/kg/d) – – 9,040 ± 705 12,987 ± 1,274 20.47 ± 1.43
Vehicle – + 8,933 ± 1,040 12,387 ± 1,169 23.11 ± 4.43
Vehicle + – 3,233 ± 280 6,445 ± 380 1.61 ± 0.16
Vehicle + + 2,600 ± 654 5,860 ± 850 1.76 ± 0.10
DβHB (0.4 mmol/kg/d) + – 3,168 ± 625 5,392 ± 847 1.80 ± 0.12
DβHB (0.8 mmol/kg/d) + – 3,720 ± 185 7,693 ± 659 2.00 ± 0.39
DβHB (1.6 mmol/kg/d) + – 6,300 ± 506A 9,597 ± 601 3.73 ± 0.10B
LβHB (1.6 mmol/kg/d) + – 2,780 ± 236 7,525 ± 360 1.10 ± 0.33
DβHB (1.6 mmol/kg/d) + + 1,947 ± 389 4,627 ± 701 1.73 ± 0.27
Animals with pumps containing either vehicle (saline) or different isoforms of β-hydroxybutyrate were inject-
ed intraperitoneally with MPTP, 3-NP, or saline (not shown). Data represent mean ± SEM of six to nine mice
per group. AP < 0.01 and BP < 0.05 compared with the saline-MPTP group.
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infused with DβHB, less reduction in SNpc TH-positive
neurons and striatal TH ODs was observed (Table 1; Fig-
ure 2, f and n). To control for the specificity of DβHB
neuroprotection, another set of MPTP-injected mice
received infusion of the inactive isomer LβHB. In these
mice, the loss of dopaminergic neurons was as severe as
in mice infused with vehicle (Table 1; Figure 2, g and o).
Thus, DβHB, but not its inactive isomer, can attenuate
neurotoxic effects of MPTP on dopaminergic cell bodies
in the SNpc and nerve fibers in the striatum.
DβHB attenuates the loss of dopamine and the motor deficit
induced by MPTP. To examine whether DβHB protects
not only against structural damage but also against
functional deficits caused by MPTP, we assessed levels of
dopamine and two of its metabolites, dihydroxyphenyl-
acetic acid (DOPAC) and homovanillic acid (HVA), in
ventral midbrain and striatum, as well as locomotor
activity, in these animals. In MPTP-injected mice that did
not receive DβHB, there was a reduction in dopamine
and its metabolites (Table 2) in both ventral midbrain
and striatum. Behaviorally, the length of time that these
MPTP-injected mice remained on the rotating rods was
significantly shorter than that of the saline-injected con-
trols (Figure 3). The motor deficit observed in MPTP-
treated mice was alleviated by the administration of 
L-DOPA/benserazide (data not shown), indicating that
this motor deficit results from a loss of dopamine. In
MPTP-injected mice that did receive DβHB, the levels of
dopamine and its metabolites were all significantly high-
er than those in MPTP-injected mice that did not receive
DβHB (Table 2). Of note, the attenuation of MPTP-
induced dopamine loss by DβHB was smaller than the
attenuation of MPTP-induced SNpc neuronal death by
DβHB. Similarly, MPTP-injected mice that received
DβHB performed much better on the rotating rods than
MPTP-injected mice that did not receive DβHB (Figure
3). Saline-injected mice that received DβHB had similar
levels of dopamine and metabolites (Table 2) and simi-
Figure 2
Protective effect of DβHB against MPTP-
induced neurodegeneration. (a–h) TH-pos-
itive neurons in SNpc, and (i–p) TH-posi-
tive terminals in striatum. Animals were
infused subcutaneously with vehicle (saline;
a, e, i, and m), DβHB (1.6 mmol/kg/d; b,
d, f, h, j, l, n, and p), or LβHB (1.6
mmol/kg/d; c, g, k, and o) 1 day before
receiving intraperitoneal injections of either
saline (a–d and i–l) or MPTP (18 mg/kg;
e–h and m–p). There is an extensive loss of
TH-positive neurons (e) and terminals (m)
in MPTP-injected animals. This loss is
attenuated by DβHB (f and n) but not by
its inactive isomer LβHB (g and o). The
complex II inhibitor 3-NP was given
intraperitoneally (15 mg/kg) daily for the
entire period of DβHB infusion. In the pres-
ence of 3-NP, DβHB does not confer neu-
roprotection. Scale bars: 500 µm (a–h) and
1 mm (i–p). Please refer to Table 1 for
quantification of neurons and terminals in
each animal group.
Table 2
Levels of dopamine and its metabolites in ventral midbrain and striatal tissues
Ventral midbrain levels (ng/mg tissue) Striatal levels (ng/mg tissue)
DA DOPAC HVA DA DOPAC HVA
Vehicle 0.32 ± 0.01 0.098 ± 0.003 1.07 ± 0.02 15.81 ± 0.69 0.91 ± 0.06 1.41 ± 0.03
DβHB 0.33 ± 0.02 0.104 ± 0.010 1.09 ± 0.11 16.92 ± 0.53 1.02 ± 0.01 1.40 ± 0.11
Vehicle/MPTP 0.17 ± 0.01 0.046 ± 0.003 0.50 ± 0.03 0.86 ± 0.21 0.10 ± 0.02 0.36 ± 0.05
DβHB/MPTP 0.23 ± 0.01A 0.070 ± 0.005A 0.71 ± 0.05A 2.41 ± 0.45B 0.24 ± 0.03B 0.64 ± 0.04A
Animals from the Rotarod study were killed, and their brains were removed and measured by HPLC for the levels of dopamine and its metabolites. Data rep-
resent mean ± SEM of 4–13 mice per group. AP < 0.01; BP < 0.05 compared with the MPTP-treated group without DβHB.
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lar motor performance (Figure 3) to those of saline-
injected mice that did not receive DβHB.
DβHB does not affect MPTP activation. MPTP is a pro-
toxin whose effect correlates with the striatal content of
its active metabolite MPP+ (30). Striatal levels of MPP+
90 minutes after the last injection of MPTP did not dif-
fer between mice that received DβHB (30.9 ± 1.6 µg/g
tissue) or vehicle [26.8 ± 1.3 µg/g tissue; Student’s t test
with 6 degrees of freedom (t(6)) = 1.98; P = 0.1]. MPTP-
induced dopaminergic neurotoxicity relies on the entry
of MPP+ into dopaminergic neurons via dopamine
transporters (31). DβHB did not impair the uptake of
[3H]MPP+ by striatal synaptosomes at concentrations
up to 5 mM, which is more than five times the plasma
concentration found in DβHB-infused animals (vehicle,
100% ± 2.3% of control; DβHB, 99.1% ± 1.8% of control;
t(6) = 0.3; P = 0.8). Inside dopaminergic neurons, MPP+
is concentrated within mitochondria by a mechanism
that depends on mitochondrial ∆ψm (20). At 5 mM,
DβHB did not alter the uptake of [3H]MPP+ by purified
brain mitochondria (vehicle, 100% ± 4.1% of control;
DβHB, 93.2% ± 0.5% of control; t(6) = 1.7; P = 0.1). Thus,
it is unlikely that the neuroprotective effect of DβHB in
the MPTP model of PD results from alterations in the
key MPTP toxicokinetic steps described above.
DβHB increases mitochondrial oxygen consumption. DβHB
has been used as a mitochondrial substrate (32, 33). We
thus asked whether DβHB could support oxidative
phosphorylation in brain mitochondria, and, if so,
whether it may rescue mitochondrial respiration
depressed by MPP+-mediated complex I blockade (34).
Consistent with DβHB being a mitochondrial sub-
strate, we found that it increased oxygen consumption
in a dose-dependent manner (Figure 4, a and b). The
effects of DβHB in supporting mitochondrial respira-
tion are stereospecific, since the inactive isomer LβHB
failed to improve oxidative phosphorylation (Figure 4c).
We also found that DβHB ameliorated oxygen con-
sumption impaired by different concentrations of MPP+
(Figure 4a) and of another complex I inhibitor, rotenone
(Figure 4b). At 25 µM MPP+ and 25 nM rotenone, which
we found to inhibit about 25% of the oxygen consump-
tion in glutamate- and malate-supported mitochondria,
DβHB restored completely the oxygen consumption
depressed by these inhibitors (Figure 4, a and b). At 100
µM MPP+ and 100 nM rotenone inhibits more than 90%
of the oxygen consumption in glutamate- and malate-
supported mitochondrial respiration (data not shown).
At these concentrations, DβHB restored completely the
oxygen consumption inhibited by MPP+, but only par-
tially that inhibited by rotenone (Figure 4, a and b). 
DβHB does not uncouple mitochondria. To assure that the
increase in rate of oxygen consumption induced by
DβHB is not an artifact of uncoupled mitochondria, we
measured ∆ψm. As expected, the uncoupler FCCP at 5
µM collapsed the ∆ψm in isolated mitochondria (FCCP,
419 ± 23 AFUs; no FCCP, 69 ± 2 AFUs). Conversely,
Figure 3
Protective effect of DβHB against motor deficit in MPTP-treated mice.
Animals were infused subcutaneously with either vehicle (saline) or
DβHB (1.6 mmol/kg/d) 1 day before receiving intraperitoneal injec-
tions of either saline or MPTP (18 mg/kg). Pumps were removed at day
7, and animals were allowed to recover from surgery and dehydration
for an additional 7 days before their Rotarod performance was
assessed. Motor deficit is observed in the MPTP-treated animals, but
DβHB significantly improves this impairment. DβHB does not affect
base-line motor function in saline-injected mice. n = 4–13; *P < 0.05
compared with the saline-vehicle group; #P < 0.05 compared with the
MPTP-vehicle group.
Figure 4
DβHB increases oxygen consumption in purified
brain mitochondria. Mitochondria (300 µg) were
incubated in the absence or presence of MPP+ (5 min-
utes; a) or rotenone (2.5 minutes; b) at 30°C, and
then 5 mM DβHB was added to induce oxygen con-
sumption. DβHB attenuated inhibition of mitochon-
drial respiration induced by MPP+ (a) or rotenone (b)
at indicated concentrations, which blocked about
25–90% of oxygen consumption when glutamate and
malate were used as NADH-linked substrates (data
not shown). (c) The improvement of oxygen con-
sumption by DβHB is stereospecific and is blocked by
10 mM 3-NP, a complex II inhibitor. (d) DβHB
increases oxygen consumption in a dose-dependent
and saturable fashion as seen with succinate, a com-
plex II substrate, although not as efficiently as succi-
nate does on an equimolar basis. n = 3–4.
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DβHB at concentrations as high as 5 mM had no effect
on mitochondrial ∆ψm (DβHB, 68.58 ± 3.07 AFUs; no
DβHB, 65.21 ± 3.03 AFUs; n = 5 per group; P > 0.05). We
also found that the increase in oxygen-consumption
rate produced by DβHB could be blocked by anti-
mycin A, a complex III inhibitor (base line, 4.49 ± 0.62
nmol/min/mg; DβHB, 14.14 ± 0.43 nmol/min/mg;
DβHB + antimycin A, 5.99 ± 0.95 nmol/min/mg; n = 3
per group; P > 0.05 comparing base line with the 
DβHB + antimycin A group). These experiments indi-
cate that DβHB does not uncouple mitochondria at
concentrations that increased oxygen consumption.
Effects of DβHB on mitochondrial respiration seem driven by
complex II. One product generated from the metabolism
of DβHB is NADH, which provides the driving force for
the mitochondrial respiration through complex I. Can an
increase in availability of NADH compensate for the loss
of oxygen consumption due to complex I inhibition? To
test this possibility, freeze-thawed disrupted brain mito-
chondria were incubated with MPP+, or rotenone, and
NADH. Concentrations of MPP+ and rotenone were
selected to produce complex I inhibition ranging from
about 40% to 100%, and supplementation of NADH
ranged from 0.5 to 2.5 times the normal concentration
used in the assay (Figure 5, a and b). These changes in
NADH supplementation did not modify the degree of
complex I inhibition (Figure 5, a and b). This indicates
that DβHB-derived NADH can-
not explain the improvement seen 
in mitochondrial respiration pro-
duced by DβHB.
Based on its metabolic pathway,
DβHB can also generate succinate,
which is capable of stimulating the
rate of oxygen consumption in iso-
lated brain mitochondria through
complex II. In keeping with this
metabolic pathway, we found that
both DβHB and succinate did
improve oxygen consumption in 
a dose-dependent and saturable
manner, although DβHB was not
as potent as succinate (Figure 4d).
This is not unexpected, since
DβHB has to go through several
metabolic steps to generate succi-
nate. In addition, we found that
the beneficial effects of DβHB on
mitochondrial respiration in the
presence of MPP+ or rotenone were
completely abolished by two differ-
ent complex II inhibitors, 3-NP at
10 mM (Figure 4c) and malonate at
10 mM (data not shown). Togeth-
er, these data are consistent with
the idea that DβHB increases mito-
chondrial respiration in the face of
complex I inhibition by a complex
II–dependent mechanism.
DβHB neuroprotection is abrogated by mitochondrial com-
plex II inhibition in vivo. To determine whether our in
vitro data are relevant to DβHB neuroprotection seen
in vivo, we first measured succinate levels in the brains
of DβHB-infused mice. Upon inhibition of complex II,
DβHB infusion indeed increased levels of succinate in
the brain (Figure 5c). Next, MPTP-injected mice infused
with DβHB were injected with 3-NP. This irreversible
complex II inhibitor was administered daily for the
entire period of DβHB infusion at a dosage of 15
mg/kg/d. As illustrated in Figure 5d, this regimen of 
3-NP inhibited approximately 40% of complex II activi-
Figure 5
Dose-response study of NADH in complex I activity (a and b) and brain levels of succinate
(c). In mitochondria lysed by freeze-thawing, when the inhibition of complex I activity was
titrated with different concentrations of MPP+ (a) or rotenone (b), different amounts of
NADH did not produce different responses in complex I activity (n = 4 per group). (c) Lev-
els of succinate were measured in the brains of animals treated with 18 mg/kg/d MPTP or
15 mg/kg 3-NP, or both. Levels of succinate in the group that received DβHB (1.6
mmol/kg/d) are significantly increased in the presence of 3-NP. n = 3–10 per group; 
*P < 0.05 compared with the control saline group; #P < 0.05 compared with the 3-NP group.
(d) Histochemical analysis in striatal sections shows that when animals were treated with 
3-NP (right panel) at this concentration for 8 days, there was approximately 40% reduction
in complex II activity in the striatum compared with that in the group treated with saline (left
panel). n = 5 per group; **P < 0.01. Scale bar: 500 µm.
Table 3
ATP levels in purified brain mitochondria
ATP levels (nmol/mg mitochondrial protein)
Base line (no substrate) 5.37 ± 0.30
DβHB (5 mM) 76.16 ± 6.11A
DβHB plus MPP+ (100 µM) 90.49 ± 9.73A
DβHB plus rotenone (100 nM) 25.96 ± 5.22B
DβHB plus MPP+ plus 3-NP (10 mM) 0.62 ± 0.21
DβHB plus rotenone plus 3-NP 0.73 ± 0.23
LβHB 3.85 ± 0.24
Mitochondrial samples were prepared as in the polarographical studies, and
ATP levels were measured using a luciferase kit. Data represent mean ± SEM
of four mice per group. AP < 0.01 and BP < 0.05 compared with the base-line
endogenous ATP level.
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ty in the striatum without causing cell death in either
the SNpc (Table 1) or the striatum, as evidenced by TH
or Nissl staining (Table 1; data not shown for striatal
Nissl staining). As before, DβHB protected against
MPTP neurotoxicity in mice that did not receive 3-NP.
However, DβHB failed to reduce MPTP-induced dop-
aminergic neurodegeneration in mice that did receive 
3-NP (Table 1; Figure 2, h and p). Supporting the effec-
tiveness of the 3-NP regimen in blocking complex II is
our demonstration that succinate levels in the brain
were higher in mice that received 3-NP than in those
that did not (Figure 5c). Thus, these results are consis-
tent with the hypothesis that complex II is a pivotal
mediator in DβHB’s neuroprotective effects.
DβHB does not have antioxidant effects but increases ATP pro-
duction. Inhibition of complex I by MPP+ and rotenone
generates reactive oxygen species (ROS), raising the possi-
bility that the beneficial effects of DβHB are mediated by
an antioxidant action, as previously suggested (14). In iso-
lated mitochondria, DβHB did not reduce but stimulat-
ed ROS production in the presence of rotenone or MPP+
(see Table 4). To elucidate the basis of DβHB-related ROS
production, 3-NP was added to the incubation mixture
(see Table 4). This complex II inhibitor was unable to
block the DβHB-related ROS production, thus ruling out
the possibility of a reversed flux of electrons from complex
II to complex I as the ROS generator (22, 23). Instead, we
suspected that the DβHB-related ROS resulted from addi-
tional NADH generated by DβHB metabolism. To test
this alternative possibility, phenazine methosulfate, a
compound that oxidizes NADH (21), was included in the
incubation mixture. Consistent with this possibility,
phenazine methosulfate abolished ROS production (see
Table 4). These data argue against DβHB having antioxi-
dant properties, at least in this in vitro setting.
Inhibition of complex I by MPP+ and rotenone also
impairs ATP production, raising the possibility that the
beneficial effects of DβHB are mediated by attenuation
of ATP depletion. We thus measured ATP production in
isolated brain mitochondria under conditions similar to
those of polarographical study. As shown in Table 3,
DβHB increased ATP production from a base line of
5.37 ± 0.30 nmol/mg protein to 76.16 ± 6.11 nmol/mg
protein. The increase of ATP production was not detect-
ed with the inactive isomer LβHB (3.85 ± 0.24 nmol/mg
protein). In agreement with the oxygen-consumption
data, DβHB prevented the loss of ATP production
caused by 100 µM MPP+ or 100 nM rotenone (Table 3).
Yet, upon addition of 3-NP, DβHB-related ATP produc-
tion was abolished (Table 3). Together, these data are
consistent with the contention that the effects of DβHB
seen in the polarographical studies correspond to an
increase in oxidative phosphorylation.
Discussion
The present study shows that the ketone body DβHB, a
crucial alternative source of glucose for brain energy, con-
fers protection against the structural and functional dele-
terious effects of the parkinsonian toxin MPTP; these
include degeneration of SNpc dopaminergic neurons
and striatal dopaminergic fibers, loss of striatal
dopamine, and PD-like motor deficit. The beneficial
effects of DβHB were achieved by its subcutaneous infu-
sion using osmotic mini-osmotic pumps, which, without
apparent distress, allowed its reliable continuous delivery
to the brain. While DβHB levels in the brain were stable
in DβHB-infused mice exposed to MPTP, in mice inject-
ed with saline they were higher at the beginning and then
dropped during the experimental period of 7 days.
Although the basis for these differences remains to be elu-
cidated, it is possible that the utilization of DβHB in the
brain increases rapidly following exposure to mitochon-
drial poisons such as MPTP and augments progressively
in normal brain as part of a metabolic adaptation to sus-
tained high DβHB concentrations.
Utilization of DβHB in the brain is contingent on its
conversion to acetoacetate by β-hydroxybutyrate dehy-
drogenase, which is scarce in the adult brain, especially in
the basal ganglia (35). The activity of β-hydroxybutyrate
dehydrogenase correlates with its protein content (36),
and, following MPTP administration, it is upregulated in
the ventral midbrain. MPTP-induced β-hydroxybutyrate
dehydrogenase upregulation precedes peak dopaminer-
gic neuronal death in this model (37). It can thus be envi-
sioned that β-hydroxybutyrate dehydrogenase activity
increases early enough to allow effective utilization of
DβHB by the compromised dopaminergic neurons.
A critical step in activation of MPTP is its conversion
into MPP+ by monoamine oxidase (38). The possibility
that DβHB infusion confers protection by interfering
with monoamine oxidase activity can be ruled out given
the fact that brain levels of MPP+ were similar between
mice that received and those that did not receive DβHB.
Also arguing against the possibility that DβHB confers
protection by impairing MPTP activation is the fact that
DβHB attenuates dopaminergic neuronal death in pri-
mary ventral midbrain cultures exposed to MPP+ (14).
DβHB also did not interfere with other key aspects of
Table 4
H2O2 measurements in purified brain mitochondria
Treatment Mitochondrial H2O2 production 
(pmol/min/mg protein)
DβHB (5 mM) 73.83 ± 8.04
Rotenone (100 nM) 132.39 ± 19.68
DβHB plus rotenone 506.00 ± 40.47A
DβHB plus rotenone plus 3-NP (10 mM) 522.76 ± 62.23A
DβHB plus rotenone plus PM (0.1 mM) 160.50 ± 20.62
LβHB (5 mM) plus rotenone 105.91 ± 7.45
MPP+ (500 µM) 55.24 ± 12.98
DβHB plus MPP+ 94.92 ± 6.79B
DβHB plus MPP+ plus PM 73.76 ± 6.38
LβHB plus MPP+ 54.28 ± 4.93
Mitochondrial samples similar to those in the polarographical studies were
prepared, and the fluorescence dye Amplex red was used to measure H2O2
converted from superoxide. Data represent mean ± SEM of four mice per
group. AP < 0.01 compared with the rotenone-alone group; BP < 0.05 com-
pared with the MPP+-alone group. PM, phenazine methosulfate.
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MPTP metabolism (39), such as entry of MPP+ into
dopaminergic neurons and mitochondria at concentra-
tions as high as 5 mM. Together these data indicate that
DβHB protects not by a pre–complex I mechanism but
rather by mitigating the deleterious effects of complex I
inhibition on the survival of dopaminergic neurons.
In isolated brain mitochondria, DβHB improves oxy-
gen consumption in the presence of the complex I poi-
sons MPP+ and rotenone. The DβHB effect is dose
dependent and stereospecific. The metabolism of DβHB
leads to an elevated mitochondrial [NADH]/[NAD+] ratio
due to NADH generated from the conversion of DβHB
to acetoacetate and also from the tricarboxylic acid (TCA)
cycle, whose turnover is increased by high levels of acetyl-
CoA produced by acetoacetate. NADH is used by com-
plex I to drive mitochondrial respiration. DβHB may
increase oxygen consumption by fueling mitochondria
with NADH. However, in the presence of complex I inhi-
bition by MPP+ or rotenone, NADH oxidation is impaired
and, as shown in this study, an increase in NADH content
is unable to alleviate complex I blockade.
In addition to generating NADH, increased TCA
turnover, in theory, should also lead to increases in pro-
duction of other TCA intermediates such as succinate.
Here, we show that DβHB infusion does increase brain
succinate content. While succinate is a TCA cycle sub-
strate, its oxidation by succinate dehydrogenase is cou-
pled to a transfer of electrons to ubiquinone of the mito-
chondrial respiratory chain, and thus succinate is
routinely used to support oxygen consumption in the
presence of complex I blockade. We demonstrate that
inhibition of complex II (a) abrogates DβHB-mediated
increases in oxygen consumption in isolated mitochon-
dria and (b) abolishes DβHB-mediated protective effects
on SNpc dopaminergic neurons and striatal dopamin-
ergic fibers after MPTP administration. Thus, these data
strongly support our hypothesis that the beneficial effect
of DβHB in the MPTP model of PD involves a complex
II–dependent mechanism.
It has been proposed that the ability of DβHB to
decrease MPP+ neurotoxicity in primary ventral midbrain
cultures is related to the oxidation of the coenzyme Q
couple, which should, by decreasing the semiquinone,
decrease ROS production (14). Contrary to this predic-
tion, we found, at least in isolated mitochondria, that
rather than decreasing ROS production induced by MPP+
or rotenone, DβHB enhanced it even further. These find-
ings cast doubt that DβHB protects the nigrostriatal
pathway through an antioxidant mechanism. How can
DβHB increase ROS? Succinate is the most effective
ROS-generating substrate in intact brain mitochondria
(22, 23), by stimulating a reversed flux of electrons from
complex II to complex I (22, 23). However, rotenone
blocks this ROS signal (22, 23); thus, in the context of the
present study, in which complex I is inhibited, this mech-
anism may not be operative. Instead, our data suggest
that DβHB-derived NADH, by feeding complex I, increas-
es the accumulation of electrons upstream to the block-
ade, thereby stimulating ROS production.
Mitochondrial respiration is tightly linked to ATP syn-
thesis (40). It may thus be speculated that DβHB, by
restoring oxygen consumption in MPTP-intoxicated ani-
mals, may increase ATP cellular stores. Ablation and inhi-
bition of poly(ADP-ribose) polymerase-1 (41, 42) and cre-
atine supplements (43) mitigate MPTP-induced death of
dopaminergic neurons in the SNpc by buffering ATP
depletion. These studies underscore the importance of
ATP deficit in the MPTP neurodegenerative process. In
normal rodents, dopaminergic structures represent less
than 15% of the cellular elements in the striatum (44) and
hardly more in the ventral midbrain. This renders pre-
carious any detection of ATP changes in brain tissues of
MPTP-intoxicated mice (45). To avoid this problem, we
studied the effects of DβHB on ATP production in iso-
lated brain mitochondria. By this approach, we were able
to demonstrate that DβHB does increase ATP levels in
both the absence and the presence of complex I
inhibitors. Consistent with the oxygen-consumption
data, we also found that the stimulation of ATP produc-
tion by DβHB likely relies on complex II, as inhibitors of
this electron transport chain enzyme eliminated the
effect. Data generated in isolated mitochondria may only
approximate the more complex situation found in vivo.
Despite this caveat, we believe that the most parsimo-
nious explanation for DβHB-induced neuroprotection in
the MPTP model of PD is that energy crisis is attenuated
by an enhancement of oxidative phosphorylation. It is
thus tempting to conclude that, under the current DβHB
regimen, the benefit due to the improved ATP produc-
tion overcomes the possible detriment due to the
increased ROS formation in this PD model.
The present study demonstrates that modulation of
body DβHB levels may be a straightforward neuropro-
tective strategy for the treatment of neurodegenerative
diseases such as PD. Relevant to this view is the demon-
stration that mice subjected to dietary restriction (e.g.,
alternate-day fasting) exhibit higher serum DβHB con-
centrations and are more resistant to kainic acid–
induced hippocampus damage (46) and to MPTP-
induced SNpc damage (47). At this point, however, the
long-term effects of the chronic use of DβHB on the cell
metabolism and, especially, on the mitochondrial func-
tion are not known. DβHB has been administered oral-
ly for several months to two 6-month-old infants with
hyperinsulinemic hypoglycemia (48). Despite the high
dosage (up to 32 g/d), these patients seem to tolerate
quite well. In addition, the ketogenic diets, which result
in high levels of DβHB, have been used for more than
70 years in humans as a treatment for refractory epilep-
sy and have proven safe and well tolerated.
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